Skip to main content
. 2011 Nov 20;20(3):647–652. doi: 10.1007/s00520-011-1306-6

Table 1.

Baseline demographics and disease characteristics

R-CHOP-14 (N = 409) R-CHOP-21 (N = 702)
FN No FN Overall FN No FN Overalla
N = 81 N = 328 N = 409 N = 133 N = 569 N = 704
Age in years, mean ± SD 61.1 ± 13.1 57.7 ± 15.0 58.4 ± 14.7 65.2 ± 11.8 62.0 ± 14.2 62.6 ± 13.8
Age ≥65 years, n (%) 39 (48) 129 (39) 168 (41) 85 (64) 275 (48) 361 (51)
Female, n (%) 42 (52) 129 (39) 171 (42) 70 (53) 265 (45) 327 (46)
BMI in kg/m2, mean ± SD 25.9 ± 4.4b 25.4 ± 4.9c 25.5 ± 4.8 25.5 ± 4.9 25.7 ± 4.4d 25.7 ± 4.5
ECOG performance status, n (%)
 0, 1 68 (84) 304 (93) 372 (91) 100 (75) 489 (86) 591 (84)
 2, 3, 4 13 (16) 18 (5) 31 (8) 24 (18) 48 (8) 72 (10)
 Missing 0 (0) 6 (2) 6 (1) 9 (7) 32 (6) 41 (6)
Ann Arbor stage, n (%)
 III 22 (27) 73 (22) 95 (23) 20 (15) 117 (21) 138 (20)
 IV 40 (49) 108 (33) 148 (36) 57 (43) 180 (32) 237 (34)
IPI, n (%)
 Low 14 (17) 110 (34) 124 (30) 26 (20) 184 (32) 211 (30)
 Intermediate 44 (54) 166 (51) 210 (51) 60 (45) 223 (39) 284 (40)
 High 18 (22) 18 (5) 36 (9) 26 (20) 62 (11) 88 (13)
 Missing 5 (6) 34 (10) 39 (10) 21 (16) 100 (18) 121 (17)
Bone marrow involvement, n (%) 14 (17) 41 (13) 55 (13) 26 (20) 83 (15) 109 (15)
History of co-morbidities, n (%) 48 (59) 141 (43) 189 (46) 80 (60) 292 (52) 375 (53)
No prior treatmente, n (%) 72 (89) 299 (91) 371 (91) 122 (92) 510 (90) 634 (90)
Number of risk factors for FNf, n (%)
 0 5 (6) 54 (16) 59 (14) 10 (8) 93 (16) 104 (15)
 1 16 (20) 95 (29) 111 (27) 25 (19) 137 (24) 162 (23)
 2 23 (28) 84 (26) 107 (26) 22 (17) 148 (26) 170 (24)
 3 14 (17) 63 (19) 77 (19) 36 (27) 102(18) 139 (20)
 ≥4 23 (28) 32 (10) 55 (13) 40 (30) 89 (16) 129 (18)

Known risk factors for FN are italicized

FN febrile neutropenia, BMI body mass index, ECOG Eastern Cooperative Oncology Group, IPI International Prognostic Index

aIncludes two patients for whom FN data were unavailable and who are excluded from other analyses presented

b n = 80

c n = 327

d n = 566

eNo chemotherapy, radiotherapy, or other prior treatment

fRisk factors are age ≥65 years; Ann Arbor stage III or IV; ECOG performance status ≥2; current or continuing cardiovascular, respiratory, renal, or hepatic/biliary co-morbidities; baseline serum albumin <35 g/L; baseline hemoglobin <12 g/dL; bone marrow involvement